The applications for curcumin (the most active compound of turmeric) that include fighting cancer, arthritis, diabetes, cardiovascular disease, osteoporosis, among other conditions is being investigated by scientific researchers around the globe.
Curcumin’s poor bio-availability has limited its application to fighting diseases. BCM-95™ is a curcumin formulation that provides seven times greater bio-availability (absorption and sustainability over 8 hours) than any other curcumin extract.
There have been several studies on BCM-95. Here is a list of studies with their summary:https://cure-garden.myshopify.com/pages/bcm-95-resources
A randomized, pilot study to assess the efficacy and safety in patients with active rheumatoid arthritis
The above study was conducted on 45 patients suffering from rheumatoid arthritis, randomized into three groups with patients receiving either BCM-95™ curcumin (500mg) twice daily, the prescription drug diclofenac sodium (one brand name is Voltaren®) 50mg twice daily, or a combination of the two. The results were analyzed using the clinically validated Disease Activity Score (DAS) 28 and also with the American College of Rheumatology (ACR) criteria and scores for pain and swelling in joints. The results clearly showed improvement in the patients' health in all three groups. The group that consumed BCM-95™ curcumin showed highest improvement compared to the other two groups who consumed the drugs and the endpoint scores were significantly better than the patients in the drug group. Curcumin was found to be safe with no adverse effects in this study. Around 14 percent of patients in the drug group withdrew because of adverse effects.
[Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res. March 9, 2012 doi: 10.1002/ptr.4639]
Randomized, controlled human clinical study to assess the efficacy and safety of BCM-95 & Bospure® compared to celecoxib in the management of knee osteoarthritis
A total of 28 subjects with diagnosed osteoarthritis of the knee were randomized to a 500mg blend BCM-95 curcumin and Bospure® Boswellia twice a day or to the prescription drug celecoxib (one brand name is Celebrex®) 100mg twice a day. This study was presented at the Osteoarthritis Research Symposium Internationale (OARSI) Annual World Congress on Osteoarthritis, September 15-18, 2011. San Diego, CA. The results showed that more relief was gained by people who consumed BCM-95 and Bospure blend compared to celecoxib. BCM-95 and Bospure equaled celecoxib on joint flexibility. No serious adverse effects were seen.
[Antony B, Kizhakedath R, Benny M, Kuruvilla BT. Clinical evaluation of a herbal product (Rhulief™) in the management of knee osteoarthritis. Abstract 316. Osteoarthritis cartilage. 2011;19(S1):S145-S146.]
Comparative study of the efficacy of curcumin and turmeric as chemopreventative agents in oral submucous fibrosis: A clinical and histopathological evaluation
This study was conducted with a goal to determine whether BCM-95™ curcumin and essential turmeric oil could help prevent conversion to oral cancer. Oral Submucous Fibrosis (OSMF) is a chronic disease of the oral mucosa. Premalignant lesions form, with a high progression rate to oral cancer. The study was done on the participants of three groups having 16 members respectively for a time period of six months. Group 1 received one capsule of BCM-95™ curcumin, 500mg curcuminioids, twice daily; group 2 received 12 drops of turmeric essential oil, held in the mouth, then swallowed, twice daily for an approximate dosage of 600mg, and the last group was given placebo twice daily. Results showed a reduction in oral discomfort/mouth burning significantly in the group that consumed BCM-95™ and essential turmeric oil. The authors reported “remarkable improvements after the first 15 days of use.” The study lasted six months, and there were significant reductions in disease scores for both group 1 and 2 at each measurement. After the completion of six months, seven among the 16 participants in the placebo group showed advanced disease stage compared to only one person in the BCM-95™ curcumin group. No serious adverse effects were noted in the study.
[Deepa Das A, Balan A, Sreelatha KT. Comparative study of the efficacy of curcumin and turmeric as chemopreventative agents in oral submucous fibrosis: A clinical and histopathological evaluation. Journal of Indian Academy of Oral Medicine and Radiology; April-June 2012;22(2):88-92.]
Human clinical study to evaluate the bioavailability of BCM-95
This study was conducted over 15 healthy men and women in the age group of 24-45 years. Among these, eight people were assigned to plain curcumin and the other seven were assigned to BCM-95. The results clearly indicated an overall seven-fold increase over 12 hours. Compared to the people who consumed plain curcumin, BCM-95 peaked at 1600 ng/g; plain curcumin peaked at ~230 ng/g. Two hours after ingestion, BCM-95 levels were 10-fold over plain curcumin. BCM-95 curcumin remained above 200 ng/g for 12 hours. Plain curcumin remained above 200 ng/g for less than 2 hours.
[Benny M, Antony B. Bio-availability of BioCurcumax™ (BCM-095™). Spice India. September, 2006:11-15.]
A pilot cross-over study to evaluate human oral bio-availability of BCM-95: A novel bio-enhanced preparation of curcumin
This study was conducted to compare BCM-95 curcumin’s absorption in human beings as against the absorption of plain curcumin enhanced with black pepper extract (piperine) and lecithin. The results of the study showed that compared to plain curcumin, BCM-95 curcumin had seven times greater bio-availability, which means it was absorbed seven times (or 700 percent) better than plain curcumin, and at one time measure point, showed a blood level 10 times that of plain curcumin. BCM-95 was absorbed 6.3 (630%) better than curcumin with piperine and lecithin.
[Antony B, Merina B, Iyer VS, et al. A pilot cross-over study to evaluate human oral bio-availability of BCM-95CG (Biocurcumax), A novel bio-enhanced preparation of curcumin. Ind J Pharm Sci. 2008;70(4):445-449.]
Six-month randomized placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer’s disease
In this study, a total of 34 participants were randomized to either 1 gram BCM-95 curcumin, 4 grams BCM-95 curcumin, or placebo. The study was conducted on people over 50 years of age who had a diagnosis of probable or possible Alzheimer’s disease based on the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association diagnostic criteria. Some of the study measures were the serum markers of amyloid beta, plasma isoprostanes (a measure of oxidative stress) and antioxidant status. The results clearly showed that those who had consumed 1 gram and 4 grams had reduced oxidative stress and improved antioxidant status compared to those in the placebo group. More adverse effects were seen in the placebo group than in the 1- or 4-gram group. There was a noted increase in serum amyloid beta in both 1-gram and 4-gram groups, but not in the placebo group. The authors noted that this “possibly reflected an ability of curcumin to disaggregate amyloid beta deposits in the brain, releasing the amyloid beta for circulation and disposal.”
[Baum L et al. Six-month randomized placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer’s disease. Journal of Clinical Psychopharmacology. Vol 28, Number 1, Feb 2008 pg 110-114]
Curcumin effects on blood lipid profile in a six-month human study
The study did not show any significant cholesterol lowering effects even when authors speculate curcumin has other cardioprotective physiological effects. [Elsevier Pharmacological Research 56(2007) pg 509-514.]
Oral bio-availability of BCM-95 in dogs
This study specifically focused on bio-availabilty in dogs for veterinary purposes. The study was conducted on six healthy adult male and female dogs, divided into plain curcumin and BCM-95 curcumin (reported as the veterinary NMXCC-95 designation) groups. No adverse effects were reported in the study. Results showed that the BCM-95 group had approximately seven-fold increase in absorption over plain curcumin when measured over 8 hours and approximately nine-fold increase over plain curcumin when measured for 12 hours.
[Poster presentation. Oral bio-availability of BCM-95 curcumin in dogs. 2009 ACVIM Forum/Canadian VMA Convention: June 3-6, 2009; Montréal, Québec, Canada.]
Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats
This veterinary study focused on obesity-induced pro-inflammatory state in cats and impact of BCM-95 on liver and inflammatory markers. The research showed safe usage in cats and also significant impact on interleukin 2 (IL-2) and reduction of AGP (a1-acid glycoprotein) which indicates curcumin impacts hepatocytes (liver cells) to reduce AGP, illustrating that BCM-95 is helping liver cells to behave more like liver cells in non-obese cats.
[Leray V, Freuchet B, Le Bloc’h J, Jeusette I, Torre C, Nguyen P. Effect of citrus polyphenol- and curcumin-supplemented diet on inflammatory state in obese cats. Br J Nutr. 2011 Oct;106 Suppl 1:S198-201.]
Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study
In this study on depression in animals, BCM-95 curcumin is compared to generic flouxetine (one brand name is Prozac®) and imipramine (one brand name is Tofranil®). The study showed that BCM-95 curcumin performed as well as other prescription anti-depressant drugs on all measures of depression. It also showed that addition of BCM-95 curcumin to the prescription drugs did not increase the effects of antidepressants.
[Sanmukhani J, Anovadiya A, Tripathi CB. Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: An acute and chronic study. Acta Pol Pharm. 2011 Sep-Oct;68(5):769-75.]
The effect of exercise and nutritional supplementation on proinflammatory cytokine expression in young racehorses during training
The inflammatory response to vigorous exercise ranges from the mild symptoms of delayed-onset muscle soreness to serious injuries affecting soft tissue, joint, and bone. Many studies have been undertaken on the inflammatory response to exercise in human athletes, and therefore a great deal of information is available on it; however, less information is available regarding the inflammatory response to exercise in young horses undergoing training for racing careers.
The study assessed the cytokine response to exercise in a group of young Thoroughbred racehorses during their initial training. Because of interest in nonpharmacologic approaches to control or ameliorate exercise-induced inflammation, this study also examined the anti-inflammatory effect of a nutritional supplement [containing BCM-95 curcumin, Bospure® boswellia, coenzyme Q10, glycine proprionyl-L-carnitine HCl, and D-ribose] which was fed to half of the horses undergoing training.
Twenty-five Thoroughbred horses of two years of age were followed through their initial race training. Peripheral blood samples were collected at various times during the exercise period for the quantitation of lactic acid, oxidative stress, and inflammatory cytokine gene expression. There was an intensity-dependent effect of exercise on lactate, malondialdehyde, and proinflammatory cytokine gene expression. Although training itself was associated with an overall reduction in inflammatory markers, the horses receiving the supplement showed further reductions in their indicators of inflammation. This study showcased evidence of nutritional supplementation reducing post exercise inflammation.
[Horohov DW, Sinatra ST, Chopra RK, Jankowitz S, Betancourt A, Bloomer RJ. The effect of exercise and nutritional supplementation on proinflammatory cytokine expression in young racehorses during training. J Equine Vet Sci. 2012. In Press.]
Comparative bio-availability of curcumin, turmeric, and Biocurcumax™ in traditional vehicles using non-everted rat intestinal sac model
The bio-availability of curcumin from turmeric, Biocurcumax and as plain curcumin was investigated using conventional vehicles by a non-everted rat intestinal model. The result of ex-vivo intestinal permeability studies showed an enhancement in the permeability of curcumin with the increase in lipophilicity of the vehicle used. The studies showed that the maximum permeability of curcumin was obtained from corn oil (13.4%) followed by butter (9.82%), milk (4.24%) and aqueous suspension (1.66%) in 8 hours. The study also made an interesting observation and that is the permeation of curcumin was more from turmeric and Biocurcumax than from plain curcumin. The results of the study suggest that the consumption of curcumin as turmeric/Biocurcumax in lipophilic vehicles will be more beneficial compared to plain curcumin.
[Shishu MM. Comparative bio-availability of curcumin, turmeric, and Biocurcumax™ in traditional vehicles using non-everted rat intestinal sac model. J Functional Foods. 2010;2(1):60-65.]
Curegarden represents a dream. A dream of sharing a happier, healthier body and quality of life with the use of nature's best ingredients. Botanics, when extracted for their bioactive compounds, offer a most effective approach to improving well-being and quality of life. It is based on the belief that botanicals of the highest quality would have a positive effect — without any negative side effects — on people's health. Over the years,we have seen and experienced personally the wonderful benefits of these high quality botanical products and are delighted to share them with others.
Arjuna Natural Extracts Ltd is India’s leading manufacturer and exporter of standardized botanical extracts for pharmaceutical and nutraceutical industries for over two decades. With customers in around 40 countries, the company has close to 50 patents to its credit of which majority are commercialized globally. The company has R&D tie ups with international universities from Australia, US and Japan. The highly advanced R&D unit at Arjuna is a complete research facility for phytochemistry, pharmacokinetics, formulation and development, pre-clinical and clinical studies.
FIND US ON FACEBOOK